News

In previous pre-clinical trials, MIV-210 has demonstrated very potent activity against hepatitis B virus (HBV) and has good pharmacokinetic properties, according to the companies. MIV-210 belongs to the

The drug, SPP100, was approved by the FDA in the US in March 2007 under the trade name Tekturna and by the European Union under the trade name

Authorization of the acute coronary syndromes (ACS) indication was based on positive results from two pivotal Phase III trials including more than 32,000 patients that compared Arixtra (fondaparinux)

The findings were consistent in patients switched to Angiox monotherapy from unfractionated heparin or Sanofi-Aventis's Lovenox (enoxaparin). The Medicines Company recently re-acquired rights for Angiox in Europe and

In the study – a randomized, double-blind, placebo-controlled clinical trial – patients were assigned to four weeks of treatment with either Lilly's investigational compound LY2140023; olanzapine, an atypical

The proof-of-concept study of 147 patients with primary insomnia showed that almorexant significantly improves the primary parameter of sleep efficiency (time spent sleeping while confined to bed during

The drug, called interferon alpha (IFNa), is used to clean up microscopic tumor cells that may remain in the body following surgery for the disease. It is the

The drug, known as ACAM2000, is the first biodefence vaccine to be approved as part of the US response to the 2001 bioterrorism attacks. Acambis developed ACAM2000 under

The double-blinded placebo-controlled study included 281 patients, males and females aged 18-65, with a BMI ranging from 30 to 40. The study was conducted at 19 investigation sites